Freespira
Commercial- Indications
- Panic disorder, Post-traumatic stress disorder, Panic attacks
Company intelligence / Profile preview
Freespira’s digital therapeutic has demonstrated significant clinical effectiveness in reducing or eliminating symptoms of panic disorder and PTSD. Clinical studies show rapid symptom relief within 28 days; a substantial proportion of patients remain panic attack-free at 12 months post-treatment. The solution has FDA clearance as an adjunctive treatment for these indications and has been validated in peer-reviewed research for both efficacy and cost savings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Freespira.